Production of an (A)H1N1 flu vaccine will begin today and the vaccine will hit the market by mid-November if clinical trials and the certification process go as planned, state-sponsored Adimmune Corp said yesterday.
Adimmune, otherwise known as Kuo-kwang Biotechnology Co, won a bid tendered by the Centers for Disease Control (CDC) last month to produce 5 million doses of (A)H1N1 vaccine at NT$199 each.
Adimmune deputy chief executive officer and president Ignatius Wei (魏逸之) told reporters yesterday that the company would begin injecting chicken embryos with a strain of the type A flu virus created by New York Medical College, the first step toward mass production of type A (H1N1) vaccines.
Once mass production is underway, clinical trials can begin, Wei said
The trials will be conducted by Huang Li-min (黃立民), a professor at National Taiwan University Hospital and chief of the infectious diseases division in the pediatric department.
“We will conduct clinical trial with 200 adults — half of which will be under 60 years old, and half above,” Huang said.
Following the dosage used in seasonal flu vaccines, half of the tested shots will be 15mg and the other half will be 30mg, he said.
“We are quite certain that one of them, or both, will work,” he said.
As the principle investigator of the clinical trials he needs to maintain a neutral position in terms of the drug candidates, Huang said.
“I really hope it works ... Of course, the hospital will not be working on a vaccine that we think will not work,” he said.
Given that the world’s vaccine production capacity is 900 million doses annually, it would be difficult for everyone on earth — about 6 billion people — to be vaccinated, he said.
The bad news is that swine flu is already beginning to spread, Huang said, adding that he has seen many people in his outpatient practice with the virus.
Contrary to predictions that swine flu will not begin to spread widely until the weather cools down in the fall, Huang said: “When a virus is strong enough, it will spread regardless of the temperature.”
Depending on foreign companies for type A flu vaccines would be a long shot, so Taiwan must produce its own vaccines, he said.
Given the skepticism over Adimmune’s decision to begin mass production of its vaccine even before the clinical trials are complete, Wei said: “Mass production must begin as soon as possible. Time is not on our side.”
A 200-person trial is already a larger test than what the WHO deems necessary, because the WHO considers the type A flu a common flu virus, therefore tests for its vaccine do not need to follow procedures for brand new drugs, he said.
‘HONEYMOON’ IS OVER: A political science professor said that the Tsai administration’s popularity peaked after it successfully contained COVID-19, but is waning President Tsai Ing-wen’s (蔡英文) and Premier Su Tseng-chang’s (蘇貞昌) approval ratings fell significantly this month in the wake of the government’s handling of the distribution of relief funds and stimulus coupons to people and businesses affected by the COVID-19 pandemic, a poll released yesterday by the New Power Party (NPP) showed. The poll showed that 68 percent of respondents said they were satisfied with Tsai’s performance, down 8.9 percentage points from last month, while 21 percent said they disapproved of her performance. Her approval among respondents aged 20 to 29 fell 14.7 percentage points, the largest decrease when compared with other age
Peggy Chen (陳佩琪), wife of Taipei Mayor Ko Wen-je (柯文哲), yesterday said that the Central Epidemic Command Center’s (CECC) claim that Taiwan had warned the WHO about possible human-to-human transmission of COVID-19 was “far-fetched.” The US on April 9 said that the WHO had put politics first and ignored Taiwan’s early warning in December last year, which the WHO denied the following day. The WHO said that it received an e-mail from Taiwanese authorities on Dec. 31 last year, but that “there was no mention in the message of human-to-human transmission.” Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC,
Food delivery provider Foodpanda had 564 consumer disputes from January to last month and failed to attend many mediation sessions with local governments nationwide, the Executive Yuan’s Consumer Protection Committee said. In a news release earlier this month, the committee said that it investigated consumer complaints and mediations for Foodpanda and rival Uber Eats during the period, when the number of delivery orders jumped due to the COVID-19 pandemic. Uber Eats had 80 consumer disputes, the committee said. Of Foodpanda’s consumer disputes, 368 resulted from delivery drivers canceling orders after customers could not be reached, 108 were related to the quality or quantity
PROTECTION LACKING: DPP Legislator Lai Pin-yu said that currently, victims cannot legally force online platforms to remove sexual videos or imagery of them A bill to prevent the nonconsensual distribution of imagery or videos of sexual acts between adults on Friday passed a first reading and has been forwarded to a Legislative Yuan committee to be discussed. The bill was jointly proposed by 18 Democratic Progressive Party (DPP) legislators. It seeks to promote gender equality, uphold righteous and moral social conduct and to protect the privacy of individuals, all of which would help prevent incidents similar to South Korea’s “Nth Room” case, the proposal said. The Nth Room involves a criminal investigation into the distribution of sexually exploitative videos via the Telegram app from 2018 to